Patient-Oriented Eczema Measure score: A Useful Tool for Web-Based Surveys in Patients with Atopic Dermatitis

• Published in: Acta dermato-venereologica Vol. 100; no. 10; p. adv00159
• Main Authors: Kido-Nakahara, Makiko, Nakahara, Takeshi, Yasukochi, Yumi, Ulzii, Dugarmaa, Furue, Masutaka
• Format: Journal Article
• Language: English
• Published: Sweden Acta Dermato-Venereologica 28-05-2020
• Subjects: Adolescent; Adult; Aged; Child; Comorbidity; Conjunctivitis, Allergic - diagnosis; Dermatitis, Atopic - diagnosis; Female; Food Hypersensitivity - diagnosis; Health Surveys; Humans; Hypersensitivity - diagnosis; Internet; Investigative Report; Male; Middle Aged; Predictive Value of Tests; Reproducibility of Results; Rhinitis, Allergic - diagnosis; Self Report; Severity of Illness Index; Surveys and Questionnaires; Young Adult; allergic comorbidity, atopic dermatitis, Patient-Oriented Eczema Measure, self-assessed measurement, web-based survey
• ISSN: 1651-2057; 0001-5555; 1651-2057
• DOI: 10.2340/00015555-3530

The Patient-Oriented Eczema Measure (POEM, 0-28 points) is a self-assessed, repeatable measurement tool for measuring atopic dermatitis (AD) severity. How-ever, whether POEM score is influenced by allergic comorbidities and whether POEM's severity banding is applicable in web-based surveys for AD remain unclear. A web-based questionnaire survey was conducted in 329 patients with AD. POEM, self-reported severity of AD, and comorbidity of allergic diseases including asthma, pollen rhinitis, allergic conjunctivitis, and food allergy were assessed. POEM scores were not affected by a history of comorbid allergic diseases. The severity banding for POEM scores on the web-based survey was as follows: clear/almost clear = 0, mild = 1-8, moderate = 9-21, and severe/very severe = 22-28, which was comparable to previous banding. These results suggest that POEM is useful for determining AD severity, even in web-based surveys. Patients with POEM scores above 9 points may be grouped into moderate, severe, and very severe AD.